More than one-quarter of all adults over age 65 have diabetes but there is little research on how to treat the disease in older adults….

A study with 15,000 middle-aged male physicians using multivitamins for more than 10 years showed no benefit in reducing cardiovascular events….

In an examination of the incidence of coronary heart disease in the U.S. by race and sex, black men and women had twice the rate of fatal CHD compared with white men and women….

Adding the direct renin inhibitor aliskiren to either an angiotensin-receptor blocker (ARB) or an angiotensin-converting-enzyme (ACE) inhibitor didn’t reduce heart or kidney events in type 2 diabetes patients at risk for such complications….

Researchers at Sweden’s Lund University have identified a "promising candidate" for a test that will indicate an early risk for type 2 diabetes, up to 10 years before diagnosing….

Even in men and women with an optimal cardiovascular disease (CVD) risk factor profile, the lifetime risk estimate for CVD is greater than 30%, and is more than 50% for men and women overall….

Pulse wave velocity which can be a parameter in the evaluation of cerebrovascular disease risk correlated with white matter lesion volume even after adjustment for confounding variables….

Last week we reported that the FDA advisory board had given their blessing to the new long-acting insulin, degludec. However, trying to find good information about this product, how it works, and what makes it different from insulin glargine or insulin detimir, has been next to impossible. This week, our …

Amy P. Campbell, MS, RD, CDE, and Richard S. Beaser, M.D.       Carbohydrate counting, a method of keeping track of the grams of carbohydrate one eats at meals and snacks, is a form of meal planning that has become increasingly popular.

With last week’s news that the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee has recommended the approval of degludec, we thought we’d give you an overview of this new drug’s pharmacology, the current approval status, trial results, and some of the cardiovascular safety concerns around degludec….